CORT vs NVS
Corcept Therapeutics Incorporated vs Novartis AG — AI-powered side-by-side comparison
CORT
Corcept Therapeutics Incorporated
56
Watch
VS
| Metric | CORT | NVS |
|---|
| AI Score |
56
|
75
|
| Price |
$111.83
|
$154.64
|
| P/E Ratio |
215.12×
|
23.55×
|
| ROE |
15.4%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.3%
|
74.3%
|
| Debt / Equity |
0.01×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
61.4
|
57.7
|
| Beta |
0.455
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for CORT versus NVS.
NVS leads by 19 points.
NVS scores 75/100 (Buy) versus CORT at 56/100 (Watch).
CORT Committee View
67% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 223.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- P/E of 223.5 is expensive by classic value standards — Value
- Price-to-book of 11.4x prices in significant intangible value — Value
- EPS declining -62.5% YoY despite any revenue growth — Growth
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical